RA
ACOR

Royce & Associates’s Acorda Therapeutics ACOR Stock Holding History

Royce & Associates’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-107
Closed -$9K – 1081
2020
Q4 		$9K Sell
107
-44
-29% -$4.05K ﹤0.01% 996
2020
Q3 		$9K Hold
151
– – ﹤0.01% 989
2020
Q2 		$13K Hold
151
– – ﹤0.01% 1127
2020
Q1 		$17K Sell
151
-61
-29% -$12K ﹤0.01% 1105
2019
Q4 		$52K Hold
212
– – ﹤0.01% 1036
2019
Q3 		$73K Buy
212
+11
+5% +$5.98K ﹤0.01% 1016
2019
Q2 		$185K Buy
201
+181
+905% +$222K ﹤0.01% 994
2019
Q1 		$32K Buy
20
+6
+43% +$10.8K ﹤0.01% 1082
2018
Q4 		$26K Buy
14
+1
+8% +$2.18K ﹤0.01% 1068
2018
Q3 		$32K Buy
13
+8
+160% +$24.8K ﹤0.01% 1087
2018
Q2 		$16K Buy
5
+2
+67% +$6.12K ﹤0.01% 1170
2018
Q1 		$10K Buy
+3
New +$8.98K ﹤0.01% 1186

Other funds holding ACOR

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
CCA
Canyon Capital Advisors Dallas, Texas $882M AUM 62.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royce & Associates's ACOR Position: Q1 2021 in Review

Royce & Associates sold out of Acorda Therapeutics (ACOR) in Q1 2021, closing a stake of 107 shares — an estimated $9K sold.

Royce & Associates first reported a position in ACOR in Q1 2018 and held it in 12 quarters. The position peaked at $185K in Q2 2019. 32 funds tracked by Wall St. Rank hold ACOR as of Q1 2021.

  • Royce & Associates reported no remaining Acorda Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Royce & Associates sold 107 Acorda Therapeutics shares in Q1 2021, an estimated $9K.
  • Royce & Associates first reported a position in Acorda Therapeutics in Q1 2018 and held it in 12 quarters.
  • Royce & Associates's Acorda Therapeutics position peaked at $185K in Q2 2019.
  • 32 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2021.

Based on Royce & Associates's 13F filing for Q1 2021, filed 10 May 2021.